🔬
Foundation Sciences · Biochemistry

Receptor Tyrosine Kinases

⏱️ 45–60 minutes read 📖 Biochemistry

Growth factor receptors that dimerise and autophosphorylate, activating Ras/MAPK and PI3K/Akt pathways.

📌 Learning Objectives

  • Describe the key principles of receptor tyrosine kinases.
  • Explain the clinical relevance of receptor tyrosine kinases.
  • Recognise common conditions linked to receptor tyrosine kinases in MLA-style scenarios.

📋 Overview

Growth factor receptors that dimerise and autophosphorylate, activating Ras/MAPK and PI3K/Akt pathways. This topic integrates with pathology, pharmacology and clinical medicine and is frequently tested in UK medical school exams and the MLA.

🔬 Basic Science

Growth factor receptors that dimerise and autophosphorylate, activating Ras/MAPK and PI3K/Akt pathways. Detailed mechanisms, regulation and molecular interactions underpin both normal physiology and disease.

🏥 Clinical Relevance

Targeted therapies: imatinib (BCR-ABL), trastuzumab (HER2), erlotinib (EGFR).

🧪 Investigations

Relevant laboratory tests, imaging or histological examination are used as appropriate to the clinical context.

💊 Management

Management is condition-specific; principles include addressing the underlying biochemical/structural derangement, supportive care and targeted therapy where available.

Revision Resources – expand the sections below for high-yield notes, exam pearls, key facts and further reading.

🎯 MLA High-Yield Notes & Quick Revision ⌄
High-yield topic for the UK MLA — frequently appears in SBA questions linking biochemistry concepts to clinical presentations and management decisions.
Applying biomedical science to clinical practice Diagnosis and investigation Pathophysiology of common conditions
  • Growth factor receptors that dimerise and autophosphorylate, activating Ras/MAPK and PI3K/Akt pathways.
⭐ Exam Pearls ⌄
⭐ High Yield
Insulin, EGFR, HER2, VEGFR are RTKs
Ras-Raf-MEK-ERK proliferation pathway
PI3K-Akt-mTOR survival/growth
Activating mutations drive cancer
💡 Clinical Pearl
: Targeted therapies: imatinib (BCR-ABL), trastuzumab (HER2), erlotinib (EGFR).
⚠️ Exam Tip — Common Mistakes
Confusing receptor tyrosine kinases with related but distinct mechanisms.
Memorising pathways without linking to clinical disease.
🔑 Key Facts ⌄
Insulin, EGFR, HER2, VEGFR are RTKs
Ras-Raf-MEK-ERK proliferation pathway
PI3K-Akt-mTOR survival/growth
Activating mutations drive cancer
📚 References ⌄
  1. BMJ Best Practice
  2. Robbins Basic Pathology
  3. Lippincott Illustrated Reviews: Biochemistry
  4. Wheater's Functional Histology
  5. NICE guidance where applicable.

Further Resources

Medical Portfolio & Career Development

Build a professional portfolio website for applications, audits, teaching, research and career progression.

CVtoWebsite.com →